| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Oct 27, 2011
MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
May 5, 2011
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced findings from the DISCERN AF trial, which utilized Medtronic's Reveal(R) XT insertable...
-
May 5, 2011Results Provide Evidence Supporting Potential Expansion of Indications for CRT in Symptomatic, Permanent Atrial Fibrillation Patient Population
MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Data presented as a Late Breaking Clinical Trial at Heart Rhythm 2011, the Heart Rhythm Society's 32nd Annual Scientific Sessions,...
-
May 2, 2011New Technology Adds Diagnostic Capability to the Arctic Front(R) Cardiac CryoAblation Catheter System in Treating Paroxysmal Atrial Fibrillation
MINNEAPOLIS, May 02, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval for use, and the first patient procedure using the...
-
Mar 28, 2011Late-Breaking Clinical Trials Feature One-Year Results of RESOLUTE US Study; Latest Evidence from Comprehensive Research Program Completes FDA Approval Submission
MINNEAPOLIS, Mar 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced the imminent release of the pivotal U.S. data on its Resolute(R) drug-eluting stent (DES) at ACC.11, the 60th
-
Mar 4, 2011Innovative Technology Designed to Optimize Arctic Front(R) Cardiac CryoAblation Catheter System in the Treatment of Paroxysmal Atrial Fibrillation
MINNEAPOLIS & TOLOCHENAZ, Switzerland, Mar 04, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the European launch of the Achieve(TM) Mapping Catheter, an intra-cardiac...
-
Jan 13, 2011Interventional Therapy Addresses Uncontrolled Hypertension with Renal Denervation
MINNEAPOLIS & MOUNTAIN VIEW, Calif., Jan 13, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced that it has completed the acquisition of privately-held Ardian, Inc., a developer...
-
Dec 17, 2010New Arctic Front(R) Cardiac CryoAblation Catheter System Reduces Symptoms for Patients with Common Heart Rhythm Disorder
MINNEAPOLIS, Dec 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved its Arctic Front(R) Cardiac CryoAblation...